Characteristics | Pre–WL (N=163) | Post-Tx (N=53) |
---|---|---|
67% | 62% | |
CF group | 30.66 ± 10.90 | 28.68 ± 8.81 |
Non-CF group | 56.28 ± 8.69 | 54.38 ± 8.88 |
COPD group | 69 (42.3%) | 26 (49.1%) |
Non-COPD group | 94 (57.7 | 27 (50.9%) |
Urinary cotinine concentrations (ng/ml) | Pre–WL (N=163) | Post-Tx (N=53) |
---|---|---|
89.0% (145/163) | 81.1% (43/53) | |
(< 50 ng/ml) | 95% CI 0.821 to 0.921 | 95% CI 0.685 to 0.893 |
6.1% (10/163) | 3.8% (2/53) | |
(50 ≤ X < 500 ng/ml) | 95% CI 0.033 to 0.108 | 95% CI 0.007 to 0.116 |
4.9% (8/163) | 15.1% (8/53) | |
(≥ 500 ng/ml) | 95% CI 0.078 to 0.094 | 95% CI 0.025 to 0.269 |
Urinary cotinine levels | COPD-group (n= 94) | Non-COPD group (n= 122) | ||
---|---|---|---|---|
Negative | 81.2% | 94.7% | ||
(< 350 ng/ml) | (56/69) | (89/94) | ||
Positive and Borderline | 18.8% | 5.3% | ||
(≥ 50 ng/ml) | (13/69) | (5/94) | ||
Odds ratio | 4.13 | |||
95% Cl | 1.40 to 12.22 | |||
P-value | 0.010 | |||
Negative | 61.5% | 100% | ||
(< 50 ng/ml) | (16/26) | (27/27) | ||
Positive and Borderline | 38.5% | 0% | ||
(≥ 50 ng/ml) | (16/26) | (27/27) | ||
Odds ratio | 35.00 | |||
95% Cl | 1.92 to 637.37 | |||
P-value | 0.016 |